Home › Funds › STRATEGIC PLANNING GROUP, LLC › VRTX
STRATEGIC PLANNING GROUP, LLC position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
STRATEGIC PLANNING GROUP, LLC reported holding 19,483 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$10.2M, representing 1.06% of its reported portfolio and ranking #38 among its reported holdings. STRATEGIC PLANNING GROUP, LLC has disclosed VRTX holdings in 5 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-10-22 · Source: SEC EDGAR Form 13F-HR
How STRATEGIC PLANNING GROUP, LLC's VRTX position evolved
STRATEGIC PLANNING GROUP, LLC first disclosed a stake in VRTX in Q4 2023 at 2,932 shares (US$1.2M). The position peaked in Q3 2026 at 19,483 shares, worth US$10.2M. Across 5 filings, STRATEGIC PLANNING GROUP, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 19,483 shares valued at US$10.2M — an increase of 817 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 2.93K | $1.19M | New |
| Q1 2024 | 3.07K | $1.28M | Add |
| Q1 2026 | 17.39K | $7.77M | New |
| Q2 2026 | 18.67K | $9.27M | Add |
| Q3 2026 | 19.48K | $10.19M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Invesco Ltd 8.04M sh · $4.00B · Q2 2026
- LOOMIS SAYLES & CO L P 3.92M sh · $1.95B · Q2 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- Clearbridge Investments, LLC 2.34M sh · $1.16B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.17M sh · $1.08B · Q2 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on STRATEGIC PLANNING GROUP, LLC
FAQ
How long has STRATEGIC PLANNING GROUP, LLC held VRTX?
STRATEGIC PLANNING GROUP, LLC has disclosed VRTX holdings in 5 of the last 12 reported quarters, going back to Q4 2023.
What is STRATEGIC PLANNING GROUP, LLC's current position in VRTX?
As of Q3 2026, STRATEGIC PLANNING GROUP, LLC holds 19.48K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $10.19M, representing 1.06% of its reported portfolio and ranking #38.
Has STRATEGIC PLANNING GROUP, LLC been buying or selling VRTX?
In the latest 13F filing (Q3 2026), STRATEGIC PLANNING GROUP, LLC increased its position in VRTX. The position peaked in Q3 2026 at 19.48K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.